Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event
Vemurafenib, a selective inhibitor of the BRAF V600 mutation, is Food and Drug Administration and European Medicines Agency approved for the treatment of stage IV metastatic melanoma alone or in combination. Among the adverse effects, cutaneous toxicity is the most common. Most of these reactions s...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Portuguesa de Dermatologia e Venereologia
2018-10-01
|
| Series: | Revista da Sociedade Portuguesa de Dermatologia e Venereologia |
| Subjects: | |
| Online Access: | https://revista.spdv.com.pt/index.php/spdv/article/view/926 |